Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study.
Journal
Nutrition & diabetes
ISSN: 2044-4052
Titre abrégé: Nutr Diabetes
Pays: England
ID NLM: 101566341
Informations de publication
Date de publication:
17 07 2023
17 07 2023
Historique:
received:
25
10
2022
accepted:
29
06
2023
revised:
11
05
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction. Survivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses. 26 patients (out of 37) with complete outcome data were included in the analysis (age ~59.0 years; BMI ~ 30.4, 35% women). Patients were hypermetabolic at T0 (30.3 ± 4.0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): -5.4 (-6.8, -4.1) kcal/kg FFM/day, p < 0.0001). 17 patients at T0 and 13 patients at T6 had hyperglycemia. None of the patients had positive islet autoantibodies. Insulin sensitivity in T0 was similarly low in hyperglycemic (H) and normoglycemic patients (N) (T0 ISI Patients with severe COVID-19 had increased REE and insulin resistance during the acute phase due to the infection and corticosteroid use, but these effects do not persist during the follow-up period. Only patients with insufficient insulin response developed hyperglycemia, indicating that beta cell dysfunction, rather than insulin resistance, was responsible for its occurrence.
Sections du résumé
BACKGROUND
COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction.
MATERIALS AND METHODS
Survivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses.
RESULTS
26 patients (out of 37) with complete outcome data were included in the analysis (age ~59.0 years; BMI ~ 30.4, 35% women). Patients were hypermetabolic at T0 (30.3 ± 4.0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): -5.4 (-6.8, -4.1) kcal/kg FFM/day, p < 0.0001). 17 patients at T0 and 13 patients at T6 had hyperglycemia. None of the patients had positive islet autoantibodies. Insulin sensitivity in T0 was similarly low in hyperglycemic (H) and normoglycemic patients (N) (T0 ISI
CONCLUSIONS
Patients with severe COVID-19 had increased REE and insulin resistance during the acute phase due to the infection and corticosteroid use, but these effects do not persist during the follow-up period. Only patients with insufficient insulin response developed hyperglycemia, indicating that beta cell dysfunction, rather than insulin resistance, was responsible for its occurrence.
Identifiants
pubmed: 37460458
doi: 10.1038/s41387-023-00241-7
pii: 10.1038/s41387-023-00241-7
pmc: PMC10352285
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Informations de copyright
© 2023. The Author(s).
Références
Aust Crit Care. 2023 Jul;36(4):579-585
pubmed: 35820985
Clin Nutr ESPEN. 2021 Aug;44:211-217
pubmed: 34330468
Am J Clin Nutr. 1990 Feb;51(2):241-7
pubmed: 2305711
Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E654-67
pubmed: 17077342
N Engl J Med. 2020 Aug 20;383(8):789-790
pubmed: 32530585
JPEN J Parenter Enteral Nutr. 2020 Sep;44(7):1174-1184
pubmed: 32462719
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Front Endocrinol (Lausanne). 2022 Feb 17;13:780663
pubmed: 35250853
PLoS One. 2022 Nov 9;17(11):e0275381
pubmed: 36350895
Am J Physiol Endocrinol Metab. 2021 Jan 1;320(1):E169-E177
pubmed: 33252253
BMC Endocr Disord. 2021 Mar 26;21(1):56
pubmed: 33771154
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1009-e1019
pubmed: 34718627
Diabetes Care. 2021 Dec;44(12):2645-2655
pubmed: 34625431
Nutr Diabetes. 2022 Aug 5;12(1):35
pubmed: 35931683
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
iScience. 2022 May 20;25(5):104322
pubmed: 35502320
Diabetologia. 2021 Jul;64(7):1480-1491
pubmed: 33907860
Electrophoresis. 2015 Aug;36(16):1969-75
pubmed: 25639649
Metabolism. 1988 Mar;37(3):287-301
pubmed: 3278194
Nat Metab. 2021 Jun;3(6):774-785
pubmed: 34035524
Diabetes. 2018 Feb;67(2):278-290
pubmed: 29203512
JPEN J Parenter Enteral Nutr. 2016 Feb;40(2):159-211
pubmed: 26773077
Am J Physiol. 1995 Mar;268(3 Pt 1):E501-13
pubmed: 7900796
BMJ Open Diabetes Res Care. 2020 Jul;8(1):
pubmed: 32719077
Cells. 2020 Nov 13;9(11):
pubmed: 33202960
Diabetologia. 2020 Dec;63(12):2548-2558
pubmed: 33029657
Crit Care. 2020 Sep 28;24(1):581
pubmed: 32988390
Cell Metab. 2021 Nov 2;33(11):2174-2188.e5
pubmed: 34599884
J Appl Physiol Respir Environ Exerc Physiol. 1983 Aug;55(2):628-34
pubmed: 6618956
Cells. 2022 Mar 09;11(6):
pubmed: 35326383
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Nutr ESPEN. 2021 Oct;45:341-350
pubmed: 34620338
Diabetes Obes Metab. 2021 Mar;23(3):870-874
pubmed: 33245182
Clin Nutr ESPEN. 2021 Jun;43:383-389
pubmed: 34024544
Am J Clin Nutr. 1982 Nov;36(5):936-42
pubmed: 7137077
Crit Care. 2021 Dec 17;25(1):437
pubmed: 34920750
Nat Metab. 2022 Jan;4(1):29-43
pubmed: 34992299
Endocr Pract. 2021 Aug;27(8):834-841
pubmed: 33887468
JPEN J Parenter Enteral Nutr. 2020 Sep;44(7):1234-1236
pubmed: 32559309
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes Res Clin Pract. 2021 May;175:108695
pubmed: 33577905
Nat Metab. 2021 Feb;3(2):149-165
pubmed: 33536639
J Diabetes Sci Technol. 2011 Nov 01;5(6):1572-83
pubmed: 22226280